Globally, an estimated 22.6 million disability-adjusted life years (DALYs) are caused by blindness and vision loss due to chronic degenerative ocular diseases, accounting for nearly 1% of total DALYs.1
Our programs target chronic immune-mediated ocular inflammation and degenerative retinal diseases.
AFX-279 and AFX-718 are late stage pre-clinical non-steroid small molecules that inhibit multiple pathways that cause activation of T-cells which drives the intraocular inflammation in recurrent uveitis and scleritis. Both drugs also act to restore the normal homeostatic Th cell/Treg cell balance in the eye. These drugs are being formulated in our proprietary topically applied nanocarriers for sustained activity.
AFX-593 and AFX-680 are late stage pre-clinical small molecules for retinal degeneration caused by diabetes. These drugs act to prevent the intraocular dysmetabolosis that causes pro-inflammatory microglial activation. They prevent the chronic inflammatory microenvironment in the retina that leads to loss of retinal integrity and subsequent micro-vascular proliferation present in diabetic retinopathy .
References:
- Ophthalmic Epidemiol. 2017; Chakravarthy U, et al.